Commerzbank Aktiengesellschaft FI Purchases 83,531 Shares of Pfizer Inc. $PFE

Key Points

• Commerzbank Aktiengesellschaft FI increased its holdings in Pfizer Inc. by 22.5% during the second quarter, purchasing an additional 83,531 shares, bringing its total ownership to 454,901 shares valued at approximately $11 million.
• Pfizer reported a quarterly earnings per share (EPS) of $0.78, exceeding analysts' estimates by $0.20, and also announced a quarterly dividend of $0.43 per share, representing a yield of 6.8%.
• Analysts have varied recommendations on Pfizer's stock, with a consensus rating of "Hold" and an average price target of $28.41, amidst a backdrop of institutional ownership that currently stands at 68.36%.

Commerzbank Aktiengesellschaft FI raised its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 22.5% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 454,901 shares of the biopharmaceutical company's stock after purchasing an additional 83,531 shares during the quarter. Commerzbank Aktiengesellschaft FI's holdings in Pfizer were worth $11,027,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Bessemer Group Inc. increased its stake in Pfizer by 11.1% during the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock valued at $3,358,000 after purchasing an additional 13,228 shares in the last quarter. Capital Advisors Inc. OK increased its stake in Pfizer by 1.2% during the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock valued at $35,817,000 after purchasing an additional 17,032 shares in the last quarter. CHURCHILL MANAGEMENT Corp bought a new stake in Pfizer during the 1st quarter valued at about $8,283,000. Westbourne Investments Inc. bought a new stake in Pfizer during the 1st quarter valued at about $2,411,000. Finally, Bourne Lent Asset Management Inc. grew its stake in shares of Pfizer by 90.8% in the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company's stock worth $927,000 after acquiring an additional 18,200 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Performance

PFE opened at $25.22 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a market cap of $143.39 billion, a price-to-earnings ratio of 13.41, a PEG ratio of 0.84 and a beta of 0.55. The company's 50 day moving average is $24.83 and its 200 day moving average is $24.14. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.08.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm's revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer's payout ratio is currently 91.49%.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on PFE shares. Wall Street Zen lowered shares of Pfizer from a "buy" rating to a "hold" rating in a research note on Sunday, September 28th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Pfizer in a research note on Wednesday. Bank of America lifted their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a research note on Friday, October 3rd. Morgan Stanley lifted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 6th. Finally, UBS Group reiterated a "neutral" rating and issued a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Pfizer currently has an average rating of "Hold" and a consensus target price of $28.41.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.